A late-stage study of the cancer drug Sutent as a treatment for colon cancer has been halted because the drug is not effective enough, the drug's manufacturer, Pfizer, announced Tuesday.
The study was designed to compare the use of a combination treatment of Sutent and a type of chemotherapy with use of the chemotherapy alone. Researchers found that the combination treatment was not more effective at extending survival without cancer progression.
There were no safety issues, according to Pfizer.
Sutent is approved in the United States for treatment of advanced kidney cancer and gastrointestinal cancer, the Associated Press reported.